Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with
Lucentis® given as once monthly intravitreal injection in patients with neovascular
age-related macular degeneration (AMD).